Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07055165 · ClinicalTrials.gov registry record · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
A NA study of Prostate Cancer and Health Behavior, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- NA
- Development phase
- 466
- Enrollment target
- 1
- Study location
NCT07055165 is a NA study of Prostate Cancer and Health Behavior that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 466 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07055165, a NA study of Prostate Cancer and Health Behavior, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- NA
- Development phase
- 466 participants
- Enrollment target
- 1
- Study location
Study Summary
Prostate cancer is the most diagnosed cancer in African American men and the second-leading cause of cancer-related death. The prostate-specific antigen (PSA) test is an early detection screening tool for prostate cancer, however, knowledge about prostate cancer and screening benefits and risks and uptake of PSA screening remains low among African American men. To address this inequity, this project proposes the use of the Connect2Care App to improve knowledge of prostate cancer, screening benefits, risks and increase readiness to complete a PSA test (e.g., intentions, motivation, confidence, and self-efficacy). The primary goal of this study is to evaluate the efficacy of the Connect2Care App in a 30-day randomized control trial compared to an existing app developed by the U.S. Department of Health \& Human Services (Prevention Taskforce App). African American men between the ages of 45 and 69 from Oklahoma (N = 266), who are not up to date with PSA screening according to recommended guidelines, will be randomly assigned 1:1 to receive either app. The app feasibility will be assessed: (1) efficacy, evaluated via post-intervention differences in knowledge of prostate cancer, screening benefits and risks, (2) app engagement and accessibility, measured via self-report validated questionnaires, and (3) app acceptability, explored via semi-structured qualitative interviews. We will explore readiness to complete a PSA test and identify predictors of readiness across both study arms. The successful demonstration of the feasibility of the Connect2Care App among African American men living in Oklahoma will support expanding this intervention to African American men nationwide.
Conditions Studied
Interventions
- BEHAVIORAL Prostate Cancer Genius App
- BEHAVIORAL US Prevention Taskforce App
Study Locations (1)
Oklahoma
- TSET Health Promotion Research Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2025-07-26 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07055165
The ClinicalTrials.gov registry entry for NCT07055165 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (23% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Prostate Cancer Genius App is the first listed.
NCT07055165 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT07055165 about?
NCT07055165 is a clinical study titled "Connect2Care: Prostate Cancer Education and Screenings for African American Men". Prostate cancer is the most diagnosed cancer in African American men and the second-leading cause of cancer-related death. The prostate-specific antigen (PSA) test is an early detection screening tool for prostate cancer, however, knowledge about prostate cancer and screening benefits and risks and ...
What is the current status of trial NCT07055165?
This trial is currently recruiting. It is a NA study. The enrollment target is 466 participants. The study started on 2025-07-26. Estimated completion is 2026-12.
What conditions does trial NCT07055165 study?
This clinical trial studies the following conditions: Prostate Cancer, Health Behavior.
What interventions are being tested in trial NCT07055165?
The interventions under investigation include: Prostate Cancer Genius App (BEHAVIORAL), US Prevention Taskforce App (BEHAVIORAL).
Who is sponsoring clinical trial NCT07055165?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07055165 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.